ANDA 210527, held by Alembic. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 210527 (Doxycycline Hyclate), held by Alembic, was first approved by FDA on Jun 13, 2018, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules, USP and other antibacterial drugs, doxycycline hyclate capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 13, 2018 | Original application | Approved | None posted |
| Doxycycline HyclateEQ 50MG BASE · capsule;oral | Doxycycline Hyclate | Rx |
| Doxycycline HyclateEQ 100MG BASE · capsule;oral | Doxycycline Hyclate | Rx |
| Jul 20, 2026 | Supplement 13Labeling · Standard review | Approved | None posted |
| Jul 20, 2026 | Supplement 15Labeling · Standard review | Approved | None posted |
| Oct 25, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 25, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jun 13, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters